As the development of chemotherapy for the non-Hodgkin lymphoma (NHL), the classical CHOP regimen was not the best regimen for all NHL, and specially, not suitable for high-grade invasive lymphomas, for example, Burkitt lymphoma (BL), lymphoblastic lymphoma (LBL) and mantle cell lymphoma(MCL). The standard regimens of BL include multi-agent, dose-intensive and short treatment duration chemotherapy, such as CODOX-M/IVAC±R and R-Hyper CVAD/MA. Prophylaxis of CNSL is also an important part for BL. LBL should be treated with regimens used in ALL patients. The current chemotherapy strategy for MCL should be that rituximab is combined with regimes including high dose cytarabine induced remission and then consolidated with autologous stem cell transplantation.